Latest Halt Medical Inc. Stories
LIVERMORE, Calif., April 1, 2013 /PRNewswire/ -- Halt Medical, Inc. announced today initial commercialization results for the Acessa System and additional launch plans. "We are grateful and encouraged that virtually all our clinical trial sites expressed an interest in launching the Acessa Procedure. As of this past week, all four of our initial launch sites have purchased and performed procedures," said Jeffrey M. Cohen, Halt Medical CEO. He added, "This is testimony to the proven...
LIVERMORE, Calif., March 12, 2013 /PRNewswire/ -- Halt Medical, Inc. announced that Dr. Jay M. Berman, M.D., FACOG, has performed the first commercial Acessa Procedure in the United States. The procedure is used for the treatment of uterine fibroids. Dr. Berman performed the procedure at the Berry Surgery Center in Farmington Hills, MI, an outpatient facility affiliated with the Detroit Medical Center's DMC Sinai-Grace Hospital. "We are extremely happy that Dr. Berman, the Wayne...
LIVERMORE, Calif., Feb. 11, 2013 /PRNewswire/ -- Halt Medical, Inc. announced today that on January 18, 2013, COFEPRIS, a division within the Mexican Ministry of Health (Secretaria de Salud) responsible for medical device oversight, issued registration for the Acessa System to treat symptomatic uterine fibroids. "Mexico is the second largest market for medical devices in Latin America," said Jeffrey Cohen, Halt's Chief Executive Officer. "We are very excited to have the opportunity...
LIVERMORE, Calif., Jan. 9, 2013 /PRNewswire/ -- Halt Medical, Inc. introduced today a team to drive commercialization of the Acessa System, a newly FDA cleared medical device to treat uterine fibroids. "It gives me great pleasure to introduce Rodney Marcy as our Senior Vice President of Sales and Marketing," said Jeffrey Cohen, Halt's Chief Executive Officer. "Rodney has extensive commercial experience in the medical device field, and women's health sector. This will be instrumental...
BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) ("American Capital") announced today that in December 2012 it invested $6.2 million ($10.7 million including investments by affiliates) in portfolio company Halt Medical, Inc., a medical device company focused on women's health. The investment supports the commercialization of the Acessa(TM) System, a newly FDA cleared medical device to treat uterine fibroids. "American Capital is pleased to be a...
LIVERMORE, Calif., Jan. 2, 2013 /PRNewswire/ -- Halt Medical, Inc. announced today that it has received $15 million of financing to support commercialization of the Acessa(TM) System, a newly FDA cleared medical device to treat uterine fibroids. (Logo: http://photos.prnewswire.com/prnh/20130102/LA35495LOGO ) "We are delighted that American Capital, Ltd. has chosen to once again lead financing for this critical new medical device," stated Jeff Cohen, Halt Medical Chief Executive...
Halt Medical, Inc. announced that it has closed on the first $20 million of a planned $50 million debt and equity financing. Livermore, CA (PRWEB) March 12, 2012 Halt Medical, Inc. announced that it has closed on the first $20 million of a planned $50 million debt and equity financing. “Leading the financing with the first $20 million is our long term investment partner American Capital Strategies (ACAS). American Capital’s financial resources, global perspective and life science...
BETHESDA, Md., March 13, 2012 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) announced today that it has invested $11.7 million, $20 million together with its affiliates, in the debt and equity of portfolio company Halt Medical, Inc., a medical device company focused on women's health. "American Capital is pleased to be supporting our portfolio company Halt Medical as it continues to grow its medical device business focused on treating uterine fibroids," said Gordon O'Brien,...
LIVERMORE, Calif., Feb. 11, 2012 /PRNewswire/ -- Halt Medical, Inc. announced today that it has closed on the first $20 million of a planned $50 million debt and equity financing. "Leading the financing with the first $20 million is our long term investment partner American Capital Strategies (ACAS). American Capital's financial resources, global perspective and life science expertise has made them the perfect financing partner for Halt Medical. Following the lead of American...
BETHESDA, Md., Dec. 20, 2010 /PRNewswire/ -- Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress. "Uterine fibroids are the leading cause...
